Chimeric: Media Thread, page-589

I think you need to do a bit more research into all of those ideas you posted. What was that bonus and when did it stop? Its all explained in the CHM announcements.That is how poaching high flyer leadership works in the US. Using her experience in CarT development has saved CHM more in time and money than any bonus she received. CarT is a very expensive treatment. Any waste of drug or time becomes very expensive. She knows what endpoints are needed for the FDA and she knows how to achieve these efficiently.

If the results gained from the Phase 1A trial into GBM and be repeated in the Phase 1B an accelerated pathway to approval is pretty much a given. And those results were achieved with the drug being used as a 4th line of treatment. The phase 1B has moved that to second line of treatment. There is no SOC for GBM. CHM are targeting a cancer with an unmet need, and no cure. The results from the Phase 1A were superior to whats available now.